- Isoniazid preventive therapy completion and factors 1
- associated with non-completion among patients on 2
- antiretroviral therapy at Kisenyi Health Centre IV, 3
- Kampala, Uganda. 4
- Short title: Isoniazid preventive therapy completion among 5
- patients on antiretroviral therapy in Kampala Uganda. 6
- 7 lan Amanya^{1,5*}, Michael Muhoozi¹, Dickson Aruhomukama^{2,3,5}, Anthony
- Ssebagereka¹, Richard Mugambe⁴. 8
- 9 ¹Department of Epidemiology and Biostatistics, School of Public Health, College of
- 10 Health Sciences, Makerere University.
- ²Department of Medical Microbiology, School of Biomedical Sciences, College of 11
- 12 Health Sciences, Makerere University.
- ³Department of Immunology and Molecular Biology, School of Biomedical Sciences, 13
- College of Health Sciences, Makerere University. 14
- 15 ⁴Department of Disease Control and Environmental Health, School of Public Health,
- 16 College of Health Sciences, Makerere University.
- ⁵Brainmann Analytics, Kampala, Uganda 17
- *Corresponding author 18
- 19 Email: ianamanya24@gmail.com (IA)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Background: Isoniazid preventive therapy (IPT) is given to HIV patients to reduce the risk of active tuberculosis (TB). However, treatment completion remains sub-optimal among those that are initiated. This study aimed to determine the completion level of IPT and the factors associated with non-completion among people on antiretroviral therapy (ART) at Kisenyi Health Center IV in Kampala, Uganda. Methods: A facility-based retrospective cohort study utilizing routinely collected data of 341 randomly selected HIV patients initiated on IPT was conducted. Data extracted from the registers were used to determine the IPT completion. Modified Poisson regression with robust error variances was used to determine the associated factors of IPT non-completion while in-depth interviews were conducted to explore barriers to IPT completion from the patient's perspective. **Results:** A total of 341 patients who started on isoniazid (INH) were retrospectively followed up, with 69% (236/341) being female. Overall IPT completion was at 83%. Multivariable analysis revealed the prevalence of IPT non-completion among males was 2.24 times the prevalence among females [aPR 2.24, 95% CI: 1.40-3.58]. The prevalence of IPT non-completion among patients with a non-suppressed HIV viral load was 3.00 times the prevalence among those with a suppressed HIV viral load [aPR 3.00, 95% CI: 1.44-6.65]. Patients who were married/cohabiting had a 69% lower prevalence of IPT non-completion compared to those who were single [aPR 0.31, 95%] CI: 0.17-0.55]. Lack of IPT-related health education, pill burden, distance to the health facility, and patient relocation were reported as the barriers to IPT completion. Conclusion: IPT completion was found to be at 83% among the cohort studied. However, lower completion levels persist among males and HIV virally non-

- suppressed patients. Lack of IPT-related health education, pill burden, distance to the 44
- 45 health facility, and patient relocation were reported as the barriers to IPT completion.
- Interventions that target these groups of people need to be intensified. 46

Background

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

The World Health Organization (WHO) estimates a quarter of the world's population to be infected with latent Tuberculosis of which the majority live in sub-Saharan Africa which is home to about 14% of the global population (1). An estimated 10 million people developed TB disease in 2017 of whom 72% were living in sub-Saharan Africa. of those that developed TB disease, 9% were co-infected with HIV (1). Immune suppression particularly due to HIV infection greatly increases the risk of TB infection as well as latent TB progression to an active infection (2, 3). The risk of developing TB is 20 to 37 times greater in people living with HIV (PLHIV) than among those who do not have HIV (4). Antiretroviral therapy (ART) has been reported to reduce the risk of acquiring TB (5) though the risk remains higher in people with HIV; and these people are up to four times more likely to die during TB treatment (6, 7). Uganda had an estimated 1.4 million people living with HIV in 2018, of whom 72% were on ART (8). Uganda also registered about 86,000 new TB infections in 2017 of whom an estimated 40% were co-infected with HIV. Among these HIV patients, TB accounted for about 30% of all deaths (1). In Kampala, the prevalence of HIV is estimated to be about 6.9%, which is higher than the national average of 6.2% (9). Additionally, the Uganda national TB prevalence survey of 2014/15 revealed a higher bacteriologically confirmed (B+) TB prevalence of 504/100,000 in urban areas compared to 370/100,000 in rural areas (10). Kampala had the highest TB case notifications in Uganda suggesting that TB was more common in urban areas than in rural areas. WHO recommends the use of three I's (Isoniazid Preventive Therapy (IPT), intensified case finding, and infection control) to reduce the risk, and burden of TB in people living

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

with HIV (11). IPT use reduces the risk of TB disease among HIV-infected individuals by about 60% (12, 13), and this efficacy is even higher accompanied by ART (14). IPT also prevents the progression of latent TB to active TB disease (15). In 2014, Uganda adopted WHO's guidelines that recommended the use of IPT for TB prevention as part of the comprehensive HIV/AIDS care strategy (16). Despite the available evidence that IPT is effective, many countries including Uganda have had little success in implementing this recommendation (1). In Uganda, the uptake of IPT as part of the TB prevention strategy remains low and this has mainly been attributed to limited funding for IPT commodities, lack of awareness of the potential benefits of IPT, health facilities, district & implementing partners not being held accountable for IPT performance; lack of data utilization at national, district & health facility level and lack of sustained quality mentorship among other factors (17). In addition, adherence and completion of treatment among patients initiated on IPT remain major concerns as these affect its effectiveness (14). Limited studies conducted in Ethiopia, Uganda, and Malawi respectively, have documented completion levels of IPT ranging from 36 to 98% (18-20). However, few studies had documented patient reasons for failure to complete the treatment in Uganda. Understanding this was key to improving the use of IPT among ART patients. Using routinely collected data, this study aimed to assess the completion of IPT and factors associated with non-completion among patients on ART. This would inform stakeholders, help to improve IPT use and help realize its benefits

thereby reducing the risk and burden of TB among these people.

Materials and methods

Study area

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Kampala, Uganda's capital has an estimated resident population of 1.5 million people (21). However, the total population attracted by the various economic activities and services in almost doubles the resident population. The study was conducted at Kisenyi health centre IV in Kampala's central division. Kisenyi health centre IV was purposively selected as it's the largest operational health center IV in Kampala that also receives a high volume of patients in comparison to smaller health facilities that provide HIV care. The facility is financed by the government but also receives funding from donors through implementing partners. Services offered by this facility are free and include TB services, laboratory services, dental services, HIV counseling and testing, maternity services, Antenatal/EMTCT services, immunization, Early Infant Diagnosis (EID), Nutrition services, Family planning services, Postnatal services, Cancer screening, STI management, youth-friendly services, and comprehensive ART outreaches among others. The ART and TB clinics are integrated and open from Monday through Friday to accommodate the nearly 12000 active ART patients. To increase completion rates, IPT and ARV medicine refills are given out simultaneously with synchronized durations. A number of tools, including the ART dispensing logs, IPT registers, ART cards, the ART register, the viral load log, and the daily activity consumption log, among others, record the drugs that have been prescribed. The patient appointment and visit dates, patient ID, current ART regimen, number of drug days distributed, weight and height, and whether the patient was bled for viral load or CD4 are just a few of the details recorded in these instruments. Active registers are kept at the various service stations, and the tools are housed in a separate records 117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

room. The Uganda Electronic Records Management system (UgandaEMR), which is located in the records sector, also stores this data electronically. Study design This was a facility-based retrospective cohort study utilizing routinely collected data. Quantitative data extracted from the facility registers were used to answer the questions on completion of IPT and the factors associated with non-completion while qualitative data collected through in-depth interviews with patients were used to explore the barriers to IPT completion from a patient's perspective. Study population The study participants were HIV patients on ART at Kisenyi HC IV that had been initiated on IPT. To reduce recall bias, ART patients that had been initiated on IPT in September 2019 at Kisenyi HC IV were considered. **Inclusion criteria** Only ART patients initiated on IPT in September 2019. Purposively selected noncompleting ART patients for in-depth interviews who provided informed consent. Minors who provided assent and whose caretakers provided consent were included in the study. **Exclusion criteria** ART patients initiated on IPT in any period other than September 2019 and those whose records could not be traced or found at the facility were excluded from the

study. Patients who were ill, unavailable at the time of data collection and those who

had no phone contacts were excluded from in-depth interviews.

Sample size considerations

- To determine the completion of IPT and the factors associated with non-completion,
- the Yamane formula at a 0.05 level of precision was used (22). This formula was used
- due to the finite population of patients initiated on IPT.
- 143 $n = N / [1 + N (E)^2]$
- 144 Where; n = sample size, N = population size, E = level of precision.
- 145 n = 1166/ [1+1166 (0.05) 2]
- 146 n = 298

149

150

151

152

153

154

155

139

- 147 Adjusting for a 10% loss to follow-up
- 148 The minimum sample size required was 331.

Sampling procedure

A list of the patient IDs initiated on IPT during September 2019, was compiled. A random sample of 341 patients was drawn, and their records were extracted from the IPT registration using Microsoft Excel. Respondents for in-depth interviews were purposively selected from the list of non-completers. The respondent selection was stratified by age group, sex, marital status, and district of residence (Table 1).

Table 2: Planned and conducted In-depth interviews.

	Planned Interviews	Conducted Interviews
Characteristic	Number	Number
Sex		
Male	9	7
Female	9	8
Age group		
0-9	3	0
10-19	3	1

20-29	3	5
30-39	3	4
40-49	3	3
50+	3	2
Marital status		
Single	5	4
Married/cohabiting	5	6
Separated/divorced	5	5
Widowed	3	0
District of Residence		
Kampala	6	8
Wakiso	6	6
Others	6	1

In a phone call, the participants gave their permission to participate in the form of audio that was recorded. Interviews continued until they reached saturation.

Study variables

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

Dependent variable

The IPT non-completion, which was measured as a person failing to pick up their fifth consecutive monthly refill within 6 months of initiation, was the dependent variable.

Patients who had begun IPT had to return to the medical facility every month for five months starting after a 2-week assessment for any adverse effects. IPT refills were given by clinicians at the monthly visit, and they also evaluated the patient's adherence and side effects. INH was prescribed for multiple months to patients who received ART on a multi-month dispensation.

It is important to note that the Ministry of health recommends that IPT should be given to all patients with the following criteria: HIV-positive children (≥one year of age). adolescents, and adults with no signs and symptoms of TB; HIV-positive infants and children <5 years who have no signs and symptoms and active TB disease who get in contact with a person with active TB disease, irrespective of previous TPT; HIV- positive pregnant mothers with a history of contact with a TB patient after ruling out

active TB; HIV-positive pregnant mothers with a WHO Stage 3 or 4 event and/or CD4

<200 without active TB (23).

173

174

175

179

182

183

184

185

186

187

188

189

190

191

192

193

194

Independent variables

- 176 The independent variables included; age, sex, Body Mass Index (BMI), marital status,
- 177 WHO HIV clinical stage at IPT initiation, and pre-IPT HIV viral suppression (defined as
- the most recent measurement within 12 months to IPT initiation).

Data collection tools

- 180 The qualitative data was collected using a call recorder and an in-depth interview
- guide, and the quantitative data was extracted using a data extraction tool.

Data collection procedures

Data collection ran for one month. Quantitative data were extracted from the IPT register, ART cards, and the Uganda Electronic Medical Records system (EMR) using a structured data tool. Variables captured quantitatively were; Residence (District, subcounty, village), WHO HIV stage at the time of IPT initiation, IPT refill and next appointment dates, weight, height, age, sex, pre-IPT viral load result, and marital status. In-depth interviews that lasted 20-30 minutes were conducted by a trained research assistant with the help of an interview guide. Variables explored qualitatively included; IPT-related health education, challenges encountered while on IPT, and smoking and/or alcohol consumption. These variables gave rise to some of the themes presented in the findings. The interviewer introduced herself to the respondent, informed him/her about the aim of the study, duration of the interview, potential risks or benefits of participating in the study, and then sought consent to take part in the

study. All qualitative interviews were recorded with a call recording application and notes taken during the interviews.

Quality control

Training of research assistants

Two graduate research assistants were recruited and trained to take part in the study to standardize data collection procedures. The training involved a review of the study objectives, variables to be extracted, data sources and collection procedures, ethics, and confidentiality. The training ensured that the research assistants were confident, knowledgeable, and comfortable with the extraction tools, data sources, and procedures.

Pre-testing of the tools

Both the data extraction tool and interview guide were pre-tested at Kawaala Health Centre III which is a public health facility in Rubaga division, Kampala district. The tools were then appropriately adjusted based on the results from the pre-test to ensure that all the available and relevant data was captured.

Field editing of data

The principal investigator supervised the data collection exercise regularly and met with the research assistants to address any issues that arose, share experiences, lessons learned, and guide the way forward. Accuracy and completeness of all filled data collection tools were emphasized and checked daily before submission.

Data management and analysis

Data storage and entry

Raw data in form of complete tools were safely kept in a lockable shelf. The data was then entered into a password-protected data entry screen in MS Excel that was developed by the PI before being exported to STATA version 14.0 for cleaning and analysis. Recordings of in-depth interviews with unique identifiers were secured with a password, simultaneously transcribed, and translated to English verbatim. Each transcript was proofread by the PI for content accuracy and completeness before being exported to Atlas ti. version 6.0 for analysis. Final transcripts and dataset were securely stored on a password-protected computer and backed up on a secure cloud-based account.

Data analysis

Quantitative data

Data entry, cleaning, and sorting; data was entered into a developed excel data screen, and checked for completeness and logical flow. The goal was to understand and identify variables to be used in the analysis. Output was a working dataset.

Exploratory data analysis; the nature of the variables was examined, new categories and variables were generated, and unwanted variables were dropped at this stage. The goal was to gain a deeper understanding of the data and variables. Output was an analytic dataset.

Descriptive analysis; Characteristics of study participants were described using frequencies categorical variables, mean, and SD for continuous variables. IPT non-

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

completion was determined as a proportion that failed to pick up their 5th consecutive monthly refill within 6 months among those initiated. Bivariable analysis: simple modified Poisson regressions of the outcome and the predictor were run to determine factors associated with non-completion to be included in the multivariable model. The output was crude prevalence ratios and confidence intervals. Variables with a p-value < 0.2 were selected for inclusion in the multivariable model. Multivariable analysis; a modified Poisson regression model with robust error variances was run to determine the predictors of IPT non-completion. The output was adjusted prevalence ratios with corresponding confidence intervals. Variables were checked for multicollinearity before being added to the model. Variables with a p-value < 0.05 were significantly associated with IPT non-completion. **Qualitative data analysis**

All audio recordings were concurrently transcribed and translated to English verbatim. Transcripts were then proofread for accuracy by the PI before being uploaded to Atlas.ti Version 6.0 for analysis. Data analysis was conducted by a trained data analyst. Thematic analysis was used to analyze the data. Both inductive and deductive coding approaches were applied to generate the codebook (24, 25). The codebook generated during analysis was reviewed by the PI before adoption. After the review of codes with the help of the code families' option in Atlas.ti, codes were then combined, others dropped or renamed to fit under emerging themes. The results were presented as narratives along with supporting quotes per theme. The analysis was regularly reviewed by the PI at every stage to ensure the reflexivity of the interpretations.

Ethical considerations

Ethical approval for the study was sought and granted by Makerere University School of Public Health Higher Degrees, Research and Ethics Committee. Permissions were subsequently granted by the Director of Public Health Environment at KCCA and the In-charge Kisenyi HC IV. Recorded consent was also obtained from the respondents. The research assistants were trained on how to ensure privacy and confidentiality for all participants both during and after data collection. Data collection took place at the height of the COVID-19 Pandemic. As result, research assistants were provided with adequate masks and sanitizer as part of infection prevention and control (IPC) measures. In addition, In-depth interviews were conducted over the phone in place of physical interviews for IPC reasons. Consequently, participant consent was audio recorded.

Results

Description of the study population

A total of 341 records of participants were included in the analysis. About 31% (104/341) of the participants were aged 29 years and below. The median age was 33 (IQR 28 - 40). The majority of the respondents were female comprising 69% (236/341) and 54.5% (186) had a normal body weight. Additionally, 97.1% (331/341) of the participants were at the WHO HIV clinical stage1. All the participants had a viral load test done in the last 12 months with 97% (330) having a suppressed result. Regarding marital status, 58.4% (199/341) of the participants were married/cohabiting while 20.5% (70) were Divorced/separated (Table 3).

Table 4: Characteristics of the study population

Characteristic	Frequency			
Age	Non-Completers % (n) 17% (58)	Completers % (n) 83% (283)	Overall (n)	
0-29	20.2% (21)	79.8% (83)	104	
30+	15.6% (37)	84.4% (200)	237	
Sex				
Female	13.6% (32)	86.4% (204)	236	
Male	24.8% (26)	75.2% (79)	105	
ВМІ				
Normal weight	19.9% (37)	80.1% (149)	186	
Underweight	22.2% (4)	77.8% (14)	18	
Pre-obesity	14.1% (12)	85.9% (73)	85	
Class 1 obesity	12.1% (4)	87.9% (29)	33	
Class 2&3 obesity	5.3% (1)	94.7% (18)	19	
WHO HIV clinical stage				
Stage 1	16.9% (56)	83.1% (275)	331	
Stage 2&3	20.0% (2)	80.0% (8)	10	
HIV Viral suppression				
Suppressed	15.8% (52)	84.2% (278)	330	
Non-suppressed	54.6% (6)	45.4% (5)	11	
Marital status				
Single	31.7% (19)	68.3% (41)	60	
Married/cohabiting	9.5% (19)	90.5% (180)	199	
Divorced/separated	24.3% (17)	75.7% (53)	70	
widowed	25% (3)	75% (9)	12	

Description of In-depth Interview participant characteristics

In total, 15 participants—eight women and seven men—who had not finished their IPT took part in the qualitative study. Four of the individuals were single, six were married or cohabitating, and five were divorced or legally separated. The median age was 34 overall (IQR: 28.5-45). One respondent lived in Mukono district, seven respondents lived in Kampala district, six respondents lived in Wakiso district. Four participants had completed their secondary education, four had completed their primary education, and one had completed their tertiary or university education (Table 3).

Table 5: Characteristics of IDI respondents

283

284

285

286

287

288

289

290

291

Characteristic	Number
Sex	
Male	7
Female	8
Age	
Overall median age	34
Median age (male)	34
Median age (female)	35.5
Marital status	
Single	4
Married/cohabiting	6
Separated/divorced	5
Education level	
Primary education	14
Secondary education	4
Tertiary or university	1
District of Residence	
Kampala	8
Wakiso	6
Mukono	1

IPT completion

Of the 341 persons who started INH, 83% (283) patients finished the dose, compared to 17% (58) who did not. 86.4% (204) of the female participants in the IPT finished it, whereas 13.6% (32) did not. In terms of guys, 75.2% (79) finished IPT while 24.8% (26) did not. 84.2% (278) of patients with a suppressed HIV viral load finished IPT, while 15.8% (52) did not. 54.6% (6) of individuals with a non-suppressed HIV viral load did not finish IPT, compared to 45.4% (5) who did. IPT was successfully completed by 79.8% (183) of patients who were under the age of 29, compared to 20.2% (21) who were not. About 91% (180) of the patients who were married or cohabitated completed IPT, compared to 9.5% (19) who did not.

Factors associated with IPT non-completion

Bivariable analysis

The prevalence of IPT non-completion was 23% lower among patients aged 30 years and above compared to those aged 29 years and below [Crude PR 0.77, CI: 0.48-1.25]. Males had an 83% higher prevalence of IPT non-completion compared to females [Crude PR 1.83, 95% CI: 1.15-2.91]. Patients with a non-suppressed HIV viral load had a 2.46 higher prevalence of IPT non-completion compared to those with a suppressed HIV viral load [Crude PR 3.46, 95% CI: 1.91-6.28]. Patients who were married/cohabiting had a 70% lower prevalence of IPT non-completion compared to those who were single [Crude PR 0.30, 95% CI: 0.17-0.53].

Multivariable analysis

In multivariable analysis, factors significantly associated with IPT non-completion were; sex, HIV viral suppression, and marital status. The prevalence of IPT non-completion among males was 2.24 times the prevalence among females [aPR 2.24,

95% CI: 1.40-3.58]. The prevalence of IPT non-completion among patients with a nonsuppressed HIV viral load was 3.00 times the prevalence among those with a suppressed HIV viral load [aPR 3.00, 95% CI: 1.435-6.65]. Patients who were married/cohabiting had a 69% lower prevalence of IPT non-completion compared to those who were single [aPR 0.31, 95% CI: 0.17-0.55] (Table 6).

Table 7: Bivariable and multivariable analysis.

317

318

319

320

321

322

Variable	Completed No % (n)	d IPT Yes % (n)	Crude Prevalence Ratios	Adjusted Prevalence Ratios (aPR)
Overall	17% (58)	83% (283)	N/A	N/A
Age				
0-29	20.2% (21)	79.8% (83)	1.00	
30+	15.6% (37)	84.4% (200)	0.77 (0.48- 1.25)	
Sex				
Female	13.6% (32)	86.4% (204)	1.00	1.00
Male	24.8% (26)	75.2% (79)	1.83 (1.15- 2.91) *	2.24 (1.40-3.58)
WHO HIV clinical stage			,	
Stage 1	16.9% (56)	83.1% (275)	1.00	
Stage 2&3	20.0% (2)	80.0% (8)	1.18 (0.33- 4.19)	
HIV Viral load status				
Suppressed	15.8 (52)	84.2 (278)	1.00	1.00
Non-suppressed	54.6 (6)	45.4 (5)	3.46 (1.91- 6.28) ***	3.00 (1.35-6.65)
Marital status				
Single	31.7 (19)	68.3 (41)	1.00	1.00
Divorced/separated	24.3 (17)	75.7 (53)	0.77 (0.44- 1.34)	0.77 (0.43-1.38)
Married/cohabiting	9.5 (19)	90.5 (180)	0.30 (0.17- 0.53) ***	0.31(0.17-0.55)
Widowed	25 (3)	75 (9)	0.79 (0.28- 2.26)	1.07 (0.35-3.24)
BMI			,	
Normal weight	19.9% (37)	80.1% (149)	1.00	

Underweight	22.2% (4)	77.8% (14)	1.12 (0.45- 2.78)	
Pre-obesity	14.1% (12)	85.9% (73)	0.71 (0.40- 1.30)	
Class 1 obesity	12.1% (4)	87.9% (29)	0.61 (0.23- 1.60)	
Class 2&3 obesity	5.3% (1)	94.7% (18)	0.26 (0.38- 1.83)	

Level of significance <0.05*; <0.01**; <0.001***

Barriers to IPT completion

- Themes and subthemes that emerged were; 325
- 326 Theme; Knowledge about IPT.

323

324

329

336

337

- Theme: Challenges encountered while taking IPT. Subthemes: Lack of transport, 327
- Distance to the health facility, Pill burden, Relocation. 328

Theme; Knowledge about IPT

- 330 One of the reasons for non-compliance was the absence of IPT-related health
- 331 education. The respondent was unaware of his IPT initiation.
- "... I met a friend at the garage where I work who disclosed that he was on drugs and 332
- 333 had not received IPT all his life. So, I wondered why I had been given these tablets
- yet the doctor didn't tell me I had TB, I swallowed them for 2 months and got tired and 334
- stopped" single male patient 335

Theme: Challenges encountered while taking IPT

Subtheme: High pill burden

- High pill burden was another reason for IPT non-completion. This was more 338
- 339 pronounced among patients that had to take other drugs for other pre-existing
- conditions such as hypertension in addition to ART and IPT. 340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

"...the tablets to swallow are very many, I have these ART tablets, then my hypertension tablets, and then the IPT. So, at times I'd forget to swallow the IPT as it wasn't treating me for anything and I completely stopped after forgetting it thrice" Female Patient. Subtheme: Distance to the health facility Distance to the health facility was cited as a challenge as some of the patients could not afford transport every month to the health facility to pick up their IPT doses. "...the first challenge, most of us come from far and at the beginning they first gave me for a month and most of my work I am casually employed. So sometimes it would be hard for me to tell my boss there is somewhere I am going I will not be around now" Male Patient. **Subtheme: Relocation** Change of business and relocation from one place to another was cited as another reason for IPT non-completion "...when I shifted from Kisenyi to Kitebi. I didn't go with my card and when I went to get my drugs from Kitebi, they didn't give me IPT yet in Kisenyi they had given me for three months. I explained to the doctors but they told me they'd give me next time until I got fed up and returned to Kisenyi where they have again started me on IPT again" Female patient.

Discussion

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

IPT Completion

The goal of the study was to ascertain the IPT completion rate and related variables among those receiving antiretroviral therapy at Kisenyi Health Center IV in Kampala. The cohort of patients under study had an IPT completion rate of 83%, which was considered to be a comparatively high rate. This result is comparable to research from Zimbabwe and India, where studies (26, 27) indicated that 81% of HIV patients have completed IPT. This completion rate is higher than that of the SEARCH HIV test and treat trial, which was done in five communities in Uganda (28), and which Tram et al. reported at 73%. The higher completion level found by our study can be attributed to the efforts of the national Quality Improvement (QI) team at the Ministry of Health founded in January 2019 to improve IPT completion as part of a wider continuous quality improvement effort in Uganda. Situational analysis of IPT completion in high-volume facilities and coaching support for these locations across all regions 29 were part of the QI initiatives. The majority of patients receiving INH concurrently with ART lowers the expense of obtaining medication because patients wouldn't need to make as many journeys to the medical institution, which contributes to the relatively high completion rate. Despite the fact that this study indicated that IPT completion rates have increased over time, 17% of patients who begin IPT do not finish the course of treatment. If IPT is not completed, its effectiveness is reduced and the patient is once again at danger of acquiring active TB, which raises morbidity and mortality.

Factors associated with IPT non-completion among patients

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

completion in this group.

on ART Males were shown to have a higher prevalence of IPT non-completion than females. This finding is consistent with a study conducted in rural Malawi by Little et al., which found that males were more likely than females to fail to complete the study (29). The typical masculine conduct, lower uptake of facility-based services, cultural precepts. and societal conventions that obstruct men's health-seeking activities and lead to subpar treatment outcomes can all be used to explain this. To increase completion rates, this necessitates focused follow-up with male patients undergoing IPT. The study also found that patients who had a non-suppressed HIV viral load had a higher prevalence of IPT non-completion. HIV viral non-suppression has been reported to be associated with; having active TB, HIV clinical stage, duration of ART, ART regimen, baseline CD4, and ART adherence among other factors (30-32). Additionally, HIV viral non-suppression has been reported to be associated with adherence; defined as a patient's ability to follow a treatment plan, take medications at prescribed times and frequencies and follow restrictions regarding food and other medications (33). Patients who are HIV virally non-suppressed are more likely to have poor ART adherence (30, 34). This, therefore, explains the association between IPT non-completion and viral non-suppression among HIV patients. Patients who did not complete IPT were more likely to be HIV virally non-suppressed. It is possible that non-virally suppressed patients were likely to be non-adherent to ART and other associated medicines including IPT. Targeted follow-up of HIV virally non-suppressing patients on IPT is needed to reduce the prevalence of IPT non-

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

Additionally, the study found that marriage was strongly associated with a lower rate of IPT non-completion than was being single. Married individuals are more likely to be open about their status with their partners (35), which offers emotional and psychological support (36), which has been linked to improved treatment outcomes (37, 38).This can also be explained by the fact that marriage gives patients stability by allowing them to be taken care of while undergoing therapy. IPT completion rates are expected to increase if these patients' wives provide them meals on time and remind them to take their medications. This finding highlights the importance of providing ART patients, as well as those on IPT, with social support networks. These patients can benefit from social and psychological support from services like psychosocial and adherence counseling as part of the HIV care program (39). **Reasons for IPT non-completion** One of the causes of IPT non-compliance, according to this study, is a lack of health education on the topic among HIV patients. In order to improve health literacy, encompassing knowledge and life skills that support individual and communal health. health education entails consciously creating learning opportunities requiring some sort of communication (40). Numerous studies have shown that health education can enhance the effectiveness of patient care (41, 42). The lack of health education among HIV patients on the other hand is related to lower patient adherence and poor treatment outcomes (43, 44). Due to the big volumes of patients that the health workers attend to on clinic days (23, 45), health workers tend

to focus on providing drug refills neglecting to provide health education (46). In these

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

circumstances, patients receive drug refills without health education on the benefits of the drugs they have received. These patients are more likely not to adhere to treatment resulting in non-completion. Some of the respondents abandoned IPT due to the pill burden, especially for those that were on medication for other underlying health conditions such as diabetes and hypertension. This finding is similar to studies conducted in Kenya, Swaziland, Zimbabwe, and India which found that pill burden was one of the reasons for IPT noncompletion, especially for patients that had to take other drugs for underlying conditions such as hypertension in addition to ART (27, 47-50). This can be explained by the difficulty in concurrent management of all conditions as it can be complicated not only by high pill burden and increased risks of drug-drug interactions but also by overlapping toxicities and immune reconstitution inflammatory syndrome (51). IPT regimens with less frequent dosages compared to INH have been shown to be as effective for TB prevention as INH but with better safety and completion levels. A 3month weekly course of rifapentine and Isoniazid (3-HP) is as effective for TB prevention as INH, but with better safety and completion levels (52). Other regimens including 4-months of daily Rifampicin (4R), and 3-4 months of daily Isoniazid and Rifampicin (3-4HR) have also been shown to be effective for TB prevention, safe, and for shorter durations compared to 6-9-month course of INH (53-55). Regimens with shorter durations and less frequent dosages should be considered for patients with pill burden challenges to improve IPT completion levels. Distance to the health facility was cited as one of the barriers to IPT completion as patients could not afford transport every month to the health facility to pick up their IPT

doses. This echoes findings from studies conducted in Tanzania, Zimbabwe, and

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

Ethiopia which found that patients were discouraged by the need to attend clinic every month combined with the long treatment duration of IPT (26, 56, 57). A significant proportion of patients do not get ART from their nearest facility (58, 59) due to various reasons that include the fear of stigma, and the perception that care at local facilities being of lower quality compared to distant ones (59, 60). This additional distance that the patient has to travel is compounded by unpredicted commodity shortages resulting from challenges in the supply chain management (61) which leads the health workers into giving IPT doses for fewer months compared to ART that was given for a longer period. This results in the need for the patient to attend the ART clinic more frequently to obtain refills which translates into additional costs on the patient's side but also crowding at the clinic. Uganda in 2016 adopted Differentiated Service Delivery (DSD) models for both HIV testing services and treatment to cater to the needs and preferences of the increasing number of clients as well as improve the quality of services and efficiency in service delivery (23). Community-based DSD models have been documented to have benefits both to the patient and the health facility in terms of reducing the cost of obtaining ART on the patient's side, improved patient management, and reduced patient congestion at the health facility (62). These DSD models can further be utilized for giving IPT refills to patients in addition to ART. Another barrier to IPT completion among HIV patients was relocation from one place to another. When patients relocate to new areas within or outside of Kampala, they also transfer to nearby health facilities. The majority of these patients transfer to these sites without proper referral documentation in what is termed "self-transfer" (63). In this case, the transfer-in facility may not offer care continuity (in this case INH) due to

a lack of relevant documentation from the transfer-out facility (64). This finding is similar to a study done in Dar es salaam where people living with HIV who were transferred to other clinics within Dar es Salaam region after IPT initiation had significantly lower IPT completion levels compared to those that attended the same clinic (57). These findings are also similar to studies conducted in Zimbabwe and Ethiopia (26, 65). This can also be explained by patients' failure to utilize health facilities in their new localities (63). Linking patient databases to improve access and continuity of care can be explored to improve not only IPT completion but also other treatment like ART.

Study limitations

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

The study limitations were mainly related to missing and incomplete data since this was a retrospective record review of routinely collected program data. This was overcome by triangulating data from different sources i.e., IPT, ART registers, ART cards, and the UgandaEMR.

The study was conducted in one health facility in Kampala city and hence the findings may not be generalizable to other health facilities within other cities and districts in Uganda. Treatment completion was assessed by a patient picking up a refill as a proxy for actual consumption of isoniazid. It is however possible that patients might have returned to pick up another bottle of tablets without consuming all the tablets from the previous refill.

The study also explored barriers to IPT completion from the patient's perspective and did not look at the provider and system-related barriers to IPT completion. To effectively improve IPT use, barriers to its completion from the provider's perspective need to be explored as well.

Some of the planned interviews by stratification were not conducted as there were no patients/respondents in those strata. The barriers to IPT completion presented represent the patient categories that were interviewed.

The barriers to IPT completion explored may have been limited by social desirability bias. This was mitigated by employing unconditional positive regard (66).

Recommendations

503

504

505

506

507

508

509

510

511

512

513

518

519

520

521

522

523

524

- 1. The health caregivers/health workers need to provide patients with IPT-related health education before IPT initiation. Opportunities to give group health education on clinic days can be leveraged. Patient attitudes towards the therapy and consequently completion levels are likely to improve when patients are fully aware of why they are being initiated on the treatment.
- 2. There's a need for the Ministry of Health and partners to increase availability and access to other regimens of IPT with less frequent dosages compared to a 6-9 months daily dose of INH. This will reduce the pill burden, especially on patients with comorbidities, improve adherence and completion levels.
 - Health workers and health caregivers should provide and intensify treatment adherence support and counseling to HIV patients who are virally non-suppressed, not only for ART but also IPT.
 - 4. There's a need for the Ministry of health to explore the use of biometric systems and linking ART/TB clinics across health facilities to enable patients especially the mobile populations to access ART and IPT at any accredited health facility but also with accurate and timely documentation.

5. Health facilities should take advantage of community DSD models and exploit them to deliver IPT in addition to ART and other related medications to eligible patients. Additionally, multi-month ART refills synchronized with IPT should also be taken advantage of to improve uptake and completion of IPT.

6. There's need for further research on factors influencing IPT completion from the health system and provider's perspective.

Conclusion

The IPT completion level was found to be relatively high, at 83% among the cohort of patients but still, less than the expected 95%. This corresponds with a general improvement in HIV services and the monitoring of HIV services by health facilities and stakeholders. Being a male, and being HIV virally non-suppressed were significantly associated with a higher prevalence of IPT non-completion. Being married was associated with a lower prevalence of IPT non-completion. Lack of health education, pill burden, distance to the health facility, and relocation were reported as the reasons for failure to complete IPT.

Acknowledgments

Special thanks go to Vicky Kyobutungi for providing a second pair of eyes, and for the input to this work. Thanks also go to Muzoora Enock, Mirembe Annah and Namara Rebecca for the moral support accorded throughout this work.

I am also grateful to the Directorate of Public health and Environment at KCCA, administrators, and health workers of Kisenyi Health Centre IV who provided all the

records and data that were needed for this research. Special thanks go to all 547 respondents who took part in this study. 548

I also acknowledge the support accorded by my colleagues; Tusabe Joan, Tabwenda 549

Lilian, Nanfuka Harriet, Kisenyi HC IV staff; Thadoues Mugenyi, and Gerald Mwesigye.

550

Author Contributions

Ssebagereka, Richard Mugambe.

551

564

565

552 **Conceptualization:** Ian Amanya, Anthony Ssebagereka, Richard Mugambe. 553 Formal analysis: Ian Amanya, Michael Muhoozi. 554 Funding acquisition: lan Amanya. 555 **Investigation:** Ian Amanya, Anthony Ssebagereka, Richard Mugambe. 556 **Methodology:** Ian Amanya, Anthony Ssebagereka, Richard Mugambe. Project administration: lan Amanya. 557 Resources: Ian Amanya. 558 559 **Software:** Ian Amanya, Michael Muhoozi. 560 **Supervision:** Ian Amanya, Anthony Ssebagereka, Richard Mugambe. 561 Visualization: lan Amanya. 562 Writing - original draft: Ian Amanya, Dickson Aruhomukama, Anthony Ssebagereka, 563 Richard Mugambe.

Writing - review & editing: Ian Amanya, Dickson Aruhomukama, Anthony

References

566

- 567 1. WHO. Global tuberculosis report 2018. Geneva, Switzerland: World Health
- Organization; 2018. WHO/CDS/TB/2018.20. Available from: http://apps. who. 568
- int/iris/bitstream ...; 2018. 569
- 570 2. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of
- 571 tuberculosis epidemics: the role of risk factors and social determinants. Social science
- & medicine. 2009;68(12):2240-6. 572
- 573 Getachew Y, Mekonnen W. Correlates of adherence and utilization of Isoniazid
- preventive therapy in HIV patients. Journal of Microbiology and Infectious Diseases. 574
- 575 2015;5(2):45-50.
- WHO. Guidelines for intensified tuberculosis case-finding and isoniazid 576 4.
- preventive therapy for people living with HIV in resourceconstrained settings. Geneva, 577
- 578 Switzerland: WHO; 2011.
- Suthar AB, Lawn SD, Del Amo J, Getahun H, Dye C, Sculier D, et al. 579 5.
- 580 Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic
- 581 review and meta-analysis. PLoS medicine. 2012;9(7):e1001270.
- Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et 582 6.
- 583 al. The impact of antiretroviral therapy and isoniazid preventive therapy on
- 584 tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS
- 585 (London, England). 2007;21(11):1441-8.
- 586 7. Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangweni P, et al.
- Tuberculosis risk factors and mortality for HIV infected persons receiving antiretroviral 587
- therapy in South Africa. AIDS (London, England). 2010;24(12):1849. 588
- 589 8. UNAIDS. Country factsheets Uganda: UNAIDS; 2018 [Available from:
- 590 https://www.unaids.org/en/regionscountries/countries/uganda.

- MoH U. Uganda population-based HIV impact assessment (UPHIA) 2016-591 9.
- 592 2017. Ministry of Health Kampala: 2019.
- 593 MOH. The Uganda National Tuberculosis Prevalence Survey, 2014-2015 10.
- 594 Survey Report. Kampala Uganda: Ministry of Health; 2018.
- WHO. Latent tuberculosis infection: updated and consolidated guidelines for 595 11.
- 596 programmatic management. World Health Organization; 2018. Report No.:
- 597 9241550236.
- WHO. Intensified TB case finding and IPT for PLHIV in resource constrained 598 12.
- 599 settings 2011 [Available from:
- https://apps.who.int/iris/bitstream/handle/10665/44472/9789241500708 eng.pdf?seq 600
- 601 uence=1.
- 602 13. Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of
- 603 isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients
- 604 under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC public health.
- 605 2015;15:346.
- Kabali C, von Reyn C, Brooks D, Waddell R, Mtei L, Bakari M, et al. Completion 606 14.
- of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in 607
- 608 Tanzania. The International Journal of Tuberculosis and Lung Disease.
- 609 2011;15(11):1515-22.
- 610 15. Abossie A, Yohanes T. assessment of isoniazid preventive therapy in the
- reduction of tuberculosis among aRT patients in arba Minch hospital, ethiopia. 611
- Therapeutics and clinical risk management. 2017;13:361. 612
- 613 16. MOH. Isoniazid Preventive Therapy in Uganda, a health worker's DGuide.
- 614 Kampala, uganda: MOH; 2014.

- 615 17. MOH. 100-Day Accelerated Isoniazid Preventive Therapy Scale Up Plan.
- 616 Kampala, Uganda: Ministry of Health; 2019.
- 617 18. Ayele H, Van Mourik M, Bonten M. Predictors of adherence to isoniazid
- 618 preventive therapy in people living with HIV in Ethiopia. The International Journal of
- 619 Tuberculosis and Lung Disease. 2016;20(10):1342-7.
- 19. Tram KH, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, et al.
- 621 Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care. Journal
- of acquired immune deficiency syndromes (1999). 2017;76(5):e115-e7.
- 623 20. Thindwa D, MacPherson P, Choko A, Khundi M, Sambakunsi R, Ngwira L, et
- al. Completion of isoniazid preventive therapy among human immunodeficiency virus
- 625 positive adults in urban Malawi. The international journal of tuberculosis and lung
- 626 disease. 2018;22(3):273-9.
- 627 21. UBOS. National Population and Housing census 2014 Provisional Results.
- 628 2014.
- 629 22. Yamane T. Statistics: An Introductory Analysis, and New York: Harperand Row.
- 630 1967.
- 631 23. MoH. Consolidated guidelines for prevention and treatment of HIV in Uganda.
- 632 Ministry of Health Kampala; 2016.
- 633 24. Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: A
- 634 hybrid approach of inductive and deductive coding and theme development.
- 635 International journal of qualitative methods. 2006;5(1):80-92.
- 636 25. Roberts K, Dowell A, Nie J-B. Attempting rigour and replicability in thematic
- analysis of qualitative research data; a case study of codebook development. BMC
- medical research methodology. 2019;19(1):1-8.

- 639 26. Takarinda K, Choto R, Harries A, Mutasa-Apollo T, Chakanyuka-Musanhu C.
- Routine implementation of isoniazid preventive therapy in HIV-infected patients in
- seven pilot sites in Zimbabwe. Public Health Action. 2017;7(1):55-60.
- 642 27. Reddy MM, Thekkur P, Ramya N, Kamath PB, Shastri SG, Kumar RB, et al. To
- start or to complete?—Challenges in implementing tuberculosis preventive therapy
- among people living with HIV: a mixed-methods study from Karnataka, India. Global
- 645 health action. 2020;13(1):1704540.
- 646 28. Khai Hoan T, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, et
- al. Isoniazid preventive therapy completion in the era of differentiated HIV care.
- Journal of acquired immune deficiency syndromes (1999). 2017;76(5):e115.
- 649 29. Little KM, Khundi M, Barnes GL, Ngwira LG, Nkhoma A, Makombe S, et al.
- 650 Predictors of isoniazid preventive therapy completion among adults newly diagnosed
- with HIV in rural Malawi. The International Journal of Tuberculosis and Lung Disease.
- 652 2018;22(4):371-7.
- 653 30. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et
- al. Factors associated with virological non-suppression among HIV-positive patients
- on antiretroviral therapy in Uganda, August 2014–July 2015. BMC infectious diseases.
- 656 2017;17(1):1-11.
- 657 31. Chhim K, Mburu G, Tuot S, Sopha R, Khol V, Chhoun P, et al. Factors
- associated with viral non-suppression among adolescents living with HIV in Cambodia:
- a cross-sectional study. AIDS research and therapy. 2018;15(1):1-10.
- 660 32. Desta AA, Woldearegay TW, Futwi N, Gebrehiwot GT, Gebru GG, Berhe AA,
- et al. HIV virological non-suppression and factors associated with non-suppression
- among adolescents and adults on antiretroviral therapy in northern Ethiopia: a
- retrospective study. BMC infectious diseases. 2020;20(1):1-10.

- 664 33. Sahay S, Reddy KS, Dhayarkar S. Optimizing adherence to antiretroviral
- therapy. The Indian journal of medical research. 2011;134(6):835.
- 666 34. Edwards RJ, Lyons N, Samaroo-Francis W, Lavia L-O, John I, Todd S, et al.
- The expansion of a patient tracer programme to identify and return patients loss to
- follow up at a large HIV clinic in Trinidad. AIDS Research and Therapy. 2021;18(1):1-
- 669 10.
- 670 35. Amoran O. Predictors of disclosure of sero-status to sexual partners among
- 671 people living with HIV/AIDS in Ogun State, Nigeria. Nigerian journal of clinical practice.
- 672 2012;15(4):385-90.
- 673 36. Mathews C, Kuhn L, Fransman D, Hussey G, Dikweni L. Disclosure of HIV
- status and its consequences. South African medical journal= Suid-Afrikaanse tydskrif
- 675 vir geneeskunde. 1999;89(12):1238.
- 676 37. Trivedi RB, Ayotte B, Edelman D, Bosworth HB. The association of emotional
- 677 well-being and marital status with treatment adherence among patients with
- hypertension. Journal of behavioral medicine. 2008;31(6):489.
- 679 38. Aizer AA, Chen M-H, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, et al. Marital
- status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869-76.
- 681 39. McCord A, Himmelstine CL. Social Protection and HIV global literature review.
- 682 IOM. 2013.
- 683 40. WHO. Health promotion glossary of terms 2021. 2021.
- 684 41. Levine DM, Green LW, Deeds SG, Chwalow J, Russell RP, Finlay J. Health
- Education for Hypertensive Patients. JAMA. 1979;241(16):1700-3.
- 686 42. Adams RJ. Improving health outcomes with better patient understanding and
- education. Risk management and healthcare policy. 2010;3:61-72.

- 688 43. Cox K, Stevenson F, Britten N, Dundar Y. A systematic review of
- communication between patients and healthcare professionals about medicine taking
- and prescribing GKT concordance unit. URL http://www.concordance.org (medicines
- 691 partnership website). 2002.
- 692 44. Tola HH, Shojaeizadeh D, Tol A, Garmaroudi G, Yekaninejad MS, Kebede A,
- 693 et al. Psychological and Educational Intervention to Improve Tuberculosis Treatment
- 694 Adherence in Ethiopia Based on Health Belief Model: A Cluster Randomized Control
- 695 Trial. PLOS ONE. 2016;11(5):e0155147.
- 696 45. Wanyenze RK, Wagner G, Alamo S, Amanyire G, Ouma J, Kwarisima D, et al.
- 697 Evaluation of the efficiency of patient flow at three HIV clinics in Uganda. AIDS patient
- 698 care and STDs. 2010;24(7):441-6.
- 699 46. Campbell C, Scott K, Madanhire C, Nyamukapa C, Gregson S. A 'good
- hospital': nurse and patient perceptions of good clinical care for HIV-positive people
- on antiretroviral treatment in rural Zimbabwe—a mixed-methods qualitative study.
- 702 International journal of nursing studies. 2011;48(2):175-83.
- 703 47. Adams L, Mahlalela N, Talbot E, Pasipamire M, Ginindza S, Calnan M, et al.
- High completion rates of isoniazid preventive therapy among persons living with HIV
- 705 in Swaziland. The International Journal of Tuberculosis and Lung Disease.
- 706 2017;21(10):1127-32.
- 707 48. Zirma M, Chifamba N, Mujuru H, Khoza S. Use of isoniazid preventative therapy
- in HIV infected paediatric patients at Harare Central Hospital. Central African Journal
- 709 of Medicine. 2018;64(7-9):58-63.
- 710 49. Ahmed F, Malik TZ, Islam F, Muzaffar A. Assessment of Barriers in Initiation
- and Completion of Isoniazid Preventive Therapy among Household Child Contacts of

- 712 Pulmonary TB Patients in Delhi: A Mixed Method Study. Community Med.
- 713 2020;11(5):227-31.
- 714 Ngugi SK, Muiruri P, Odero T, Gachuno O. Factors affecting uptake and 50.
- 715 completion of isoniazid preventive therapy among HIV-infected children at a national
- 716 referral hospital, Kenya: a mixed quantitative and qualitative study. BMC infectious
- 717 diseases. 2020;20(1):1-11.
- Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R. Management of HIV-718 51.
- 719 associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC
- 720 medicine. 2013;11(1):1-16.
- 721 52. Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine
- 722 plus isoniazid for tuberculosis preventive treatment: a systematic review. Int J Tuberc
- 723 Lung Dis. 2018;22(12):1422-8.
- 724 53. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al.
- The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month 725
- 726 regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in
- 727 children: results of an 11-year randomized study. Clinical Infectious Diseases.
- 728 2007;45(6):715-22.
- Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four 729 54.
- 730 months of rifampin or nine months of isoniazid for latent tuberculosis in adults. New
- 731 England Journal of Medicine. 2018;379(5):440-53.
- 732 55. WHO. WHO consolidated quidelines on tuberculosis: tuberculosis preventive
- treatment: World Health Organization; 2020. 733
- 734 56. Tadesse Y, Gebre N, Daba S, Gashu Z, Habte D, Hiruy N, et al. Uptake of
- 735 isoniazid preventive therapy among under-five children: TB contact investigation as
- 736 an entry point. PLoS One. 2016;11(5):e0155525.

- perpetuity.

 It is made available under a CC-BY 4.0 International license .
- 737 57. Robert M, Todd J, Ngowi BJ, Msuya SE, Ramadhani A, Sambu V, et al.
- 738 Determinants of isoniazid preventive therapy completion among people living with HIV
- attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region,
- 740 Tanzania. A cross-sectional analytical study. BMC infectious diseases. 2020;20(1):1-
- 741 9.
- 742 58. Akullian AN, Mukose A, Levine GA, Babigumira JB. People living with HIV travel
- 743 farther to access healthcare: a population-based geographic analysis from rural
- 744 Uganda. Journal of the International AIDS Society. 2016;19(1):20171.
- 745 59. Billioux VG, Grabowski MK, Ssekasanvu J, Reynolds SJ, Berman A, Bazaale
- J, et al. HIV viral suppression and geospatial patterns of HIV antiretroviral therapy
- 747 treatment facility use in Rakai, Uganda. AIDS (London, England). 2018;32(6):819-24.
- 748 60. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD.
- 749 Transportation costs impede sustained adherence and access to HAART in a clinic
- 750 population in southwestern Uganda: a qualitative study. AIDS and Behavior.
- 751 2010;14(4):778-84.
- 752 61. Karimi A, Mishra A, Natarajan KV, Sinha KK. Managing Commodity Stock-outs
- in Public Health Supply Chains in Developing Countries: An Empirical Analysis.
- 754 Production and Operations Management. 2021;30(9):3116-42.
- 755 62. Kintu TM, Ssewanyana AM, Kyagambiddwa T, Nampijja PM, Apio PK, Kitaka
- J, et al. Exploring drivers and barriers to the utilization of community client-led ART
- delivery model in South-Western Uganda: patients' and health workers' experiences.
- 758 BMC Health Services Research. 2021;21(1):1129.
- 759 63. Hickey MD, Omollo D, Salmen CR, Mattah B, Blat C, Ouma GB, et al.
- 760 Movement between facilities for HIV care among a mobile population in Kenya:
- transfer, loss to follow-up, and reengagement. AIDS care. 2016;28(11):1386-93.

- 762 64. Wilkinson LS, Skordis-Worrall J, Ajose O, Ford N. Self-transfer and mortality
- 763 amongst adults lost to follow-up in ART programmes in low-and middle-income
- 764 countries: systematic review and meta-analysis. Tropical Medicine & International
- 765 Health. 2015;20(3):365-79.
- 766 65. Ayele HT, van Mourik MS, Bonten MJ. Effect of isoniazid preventive therapy on
- 767 tuberculosis or death in persons with HIV: a retrospective cohort study. BMC Infectious
- 768 Diseases. 2015;15(1):1-8.
- Bozarth JD. Unconditional positive regard. The handbook of person-centred 769 66.
- psychotherapy and counselling, 2nd ed. New York, NY: Palgrave Macmillan/Springer 770
- 771 Nature; 2013. p. 180-92.